Phoenix Biotech Acquisition Performance
| PBAXDelisted Stock | USD 10.90 0.00 0.00% |
The company holds a Beta of 0.0317, which implies not very significant fluctuations relative to the market. As returns on the market increase, Phoenix Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Phoenix Biotech is expected to be smaller as well. Phoenix Biotech Acqu right now holds a risk of 0.0%. Please check Phoenix Biotech Acqu value at risk, as well as the relationship between the skewness and relative strength index , to decide if Phoenix Biotech Acqu will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Phoenix Biotech Acquisition has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Phoenix Biotech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 507.9 K |
Phoenix |
Phoenix Biotech Relative Risk vs. Return Landscape
If you would invest 1,090 in Phoenix Biotech Acquisition on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Phoenix Biotech Acquisition or generate 0.0% return on investment over 90 days. Phoenix Biotech Acquisition is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Phoenix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Phoenix Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phoenix Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Phoenix Biotech Acquisition, and traders can use it to determine the average amount a Phoenix Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PBAX |
Based on monthly moving average Phoenix Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Phoenix Biotech by adding Phoenix Biotech to a well-diversified portfolio.
Phoenix Biotech Fundamentals Growth
Phoenix Stock prices reflect investors' perceptions of the future prospects and financial health of Phoenix Biotech, and Phoenix Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Phoenix Stock performance.
| Return On Asset | -0.0255 | |||
| Current Valuation | 36.13 M | |||
| Shares Outstanding | 6.23 M | |||
| Price To Book | 123.73 X | |||
| EBITDA | (5.74 M) | |||
| Cash And Equivalents | 553.77 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 650 K | |||
| Book Value Per Share | (2.20) X | |||
| Cash Flow From Operations | (1.71 M) | |||
| Earnings Per Share | (0.35) X | |||
| Total Asset | 42.37 M | |||
| Retained Earnings | (10.76 M) | |||
About Phoenix Biotech Performance
Evaluating Phoenix Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Phoenix Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Phoenix Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Phoenix Biotech Acquisition Corp. does not have significant operations. The company was incorporated in 2021 and is based in Oakland, California. Phoenix Biotech is traded on NASDAQ Exchange in the United States.Things to note about Phoenix Biotech Acqu performance evaluation
Checking the ongoing alerts about Phoenix Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Phoenix Biotech Acqu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Phoenix Biotech Acqu is now traded under the symbol CERO. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Phoenix Biotech Acqu is not yet fully synchronised with the market data | |
| Phoenix Biotech Acqu has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Phoenix Biotech Acquisition currently holds about 553.77 K in cash with (1.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 95.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Phoenix Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Phoenix Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Phoenix Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Phoenix Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Phoenix Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Phoenix Biotech's stock. These opinions can provide insight into Phoenix Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |